Enkephalins are pentapeptide endogenous opioids (met-enkephalin: Tyr-Gly-Gly-Phe-Met; leu-enkephalin: Tyr-Gly-Gly-Phe-Leu) that function as neurotransmitters and neuromodulators, primarily binding to delta opioid receptors (DOR) and, with lower affinity, to mu opioid receptors (MOR). They are synthesized from the precursor protein proenkephalin in the brain (especially periaqueductal gray and rostral ventromedial medulla), spinal cord dorsal horn, adrenal medulla, and immune cells, playing critical roles in pain modulation, stress response balancing, immune regulation, and emotional processing. Enkephalins represent the body's rapid-acting, short-lived "STOP" signal for pain and stress systems.
Think of enkephalins as fire extinguishers scattered throughout a building (your nervous system). When a fire alarm goes off (pain signal, stress response), the fire trucks arrive (CRF, norepinephrine, substance P — the "GO" signals), but you also need someone to actually put out small fires locally before they spread. Enkephalins are those quick-response extinguishers mounted on every floor. They're small, fast-acting, and get used up quickly (half-life measured in seconds). The PAG is like the fire safety coordinator who dispatches these extinguishers down the elevator shaft (descending pathways) to the ground floor (dorsal horn) where the fire is spreading. The problem? If there's a constant state of emergency (chronic stress), you run out of extinguishers. The mounting brackets are still there (delta opioid receptors on pain neurons), but the canisters are empty. Now every small spark becomes a raging fire because you've lost your first-response capability. This is why chronic stress patients develop chronic pain — they've depleted their enkephalin fire extinguishers.
¶ Synthesis and Release
Proenkephalin is cleaved by prohormone convertases (PC1 and PC2) to yield multiple copies of met-enkephalin and leu-enkephalin. These pentapeptides are stored in dense-core vesicles in neurons of the PAG, RVM, dorsal horn (Lamina II), adrenal chromaffin cells, and immune cells (particularly macrophages and T cells). Release is calcium-dependent and triggered by action potentials or immune activation signals.
¶ Receptor Binding and Signaling
Enkephalins bind preferentially to delta opioid receptors (DOR, Kd ~1 nM) > mu opioid receptors (MOR, Kd ~100 nM) > kappa opioid receptors. Both DOR and MOR are Gi/Go-coupled GPCRs that initiate the following cascade:
graph TD
A[Enkephalin binds DOR/MOR] --> B[Gi/Go protein activation]
B --> C[Adenylyl cyclase inhibition]
B --> D["Voltage-gated Ca²⁺ channels close"]
B --> E["G-protein-inwardly-rectifying K⁺ channels open"]
C --> F["↓ cAMP → ↓ PKA activity"]
D --> G["↓ Neurotransmitter release from presynaptic terminal"]
E --> H[Hyperpolarization of neuron]
F --> I["↓ CREB phosphorylation"]
G --> J[Reduced substance P, glutamate release]
H --> K[Reduced action potential firing]
I --> L[Altered gene transcription]
J --> M[Pain signal transmission blocked]
K --> M
In the PAG-RVM-dorsal horn circuit:
- PAG enkephalinergic neurons inhibit GABAergic interneurons → disinhibit RVM "OFF cells"
- RVM OFF cells (enkephalinergic) project to spinal dorsal horn Lamina II
- Dorsal horn: Enkephalins bind to presynaptic DORs on C fibers and A-delta nociceptors → close N-type Ca²⁺ channels → reduce substance P and glutamate release
- Postsynaptic effect: Enkephalins bind DORs on secondary nociceptive neurons → open K⁺ channels → hyperpolarize → reduce spinothalamic tract transmission
In the PAG and hypothalamus, enkephalins provide negative feedback on CRF and ACTH release:
- Enkephalins inhibit CRF neurons in the paraventricular nucleus
- Balance the "GO" (CRF/cortisol) with "STOP" (enkephalin/endorphin) signals
- Chronic stress depletes enkephalin → unopposed CRF → HPA axis dysregulation
Immune cells express both proenkephalin and opioid receptors:
- Macrophages release enkephalins at sites of inflammation
- Enkephalins bind DOR on immune cells → reduce TNF-α, IL-6, IL-1β production
- Modulate neutrophil chemotaxis and T cell proliferation
- Part of the neuroimmune "resolution program"
Enkephalins are rapidly degraded (half-life: 2-5 seconds) by:
- Aminopeptidase N (CD13)
- Neutral endopeptidase (neprilysin, CD10)
- Dipeptidyl peptidase IV (DPP-IV)
This rapid degradation ensures precise temporal control but also makes the system vulnerable to depletion.
¶ Chronic Stress and Pain
Chronic stress depletes enkephalin production in the PAG by 40-60%, leading to:
Patients with depleted endogenous enkephalins develop opioid tolerance faster because:
- DORs and MORs are already downregulated from chronic activation attempts
- CREB upregulation has increased dynorphin (anti-reward kappa agonist)
- The system has "given up" trying to produce endogenous analgesia
Clinical intervention requires stress reduction first (restore enkephalin synthesis) before expecting pain improvement.
¶ Depression and Anhedonia
Enkephalin deficiency contributes to depression via:
The placebo effect for pain operates substantially through enkephalin release:
- fMRI studies show PAG and anterior cingulate activation during placebo analgesia
- Naloxone (opioid antagonist) blocks 60-70% of placebo analgesia
- This is the body's own "belief → chemistry" pathway
Enkephalin-deficient states show:
- PAG enkephalin content: Drops 40-60% in chronic stress models
- CSF met-enkephalin: <10 pg/mL associated with chronic pain syndromes
- Enkephalin/substance P ratio: Inverted in fibromyalgia and chronic fatigue (normally 2:1, becomes 1:2)
- Degradation rate: T½ = 2-5 seconds (compare to beta-endorphin T½ = 20-30 minutes)
Restore synthesis:
- Stress reduction (meditation, breathwork, vagus nerve stimulation)
- exercise (acutely increases enkephalin mRNA by 200-300%)
- Adequate sleep (enkephalin synthesis peaks during REM)
Reduce degradation:
- DPP-IV inhibitors (used in diabetes) may preserve enkephalins
- Avoid chronic NSAID use (may impair opioid receptor sensitivity)
Support receptor function:
- Low-dose naltrexone (paradoxically upregulates receptors via intermittent blockade)
- Omega-3 fatty acids maintain membrane fluidity for GPCR function
- Met-enkephalin and leu-enkephalin differ by a single C-terminal amino acid (Met vs Leu)
- Half-life of 2-5 seconds makes enkephalins the shortest-lived endogenous opioids
- DOR affinity is 100-fold higher than MOR affinity (Kd ~1 nM vs ~100 nM)
- PAG enkephalin levels decrease 40-60% during chronic stress (animal models, human extrapolation)
- Proenkephalin yields 4 copies of met-enkephalin and 1 copy of leu-enkephalin per precursor
- Exercise increases enkephalin gene expression 200-300% within 30 minutes
- Acute stress increases enkephalin release; chronic stress depletes synthesis capacity
- Enkephalins are found in adrenal medulla (co-released with catecholamines during stress)
- Immune cells produce enkephalins for local anti-inflammatory "resolution" signaling
- Placebo analgesia activates enkephalinergic PAG-RVM pathway (blocked by naloxone)
- Enkephalin/substance P ratio inverts in chronic pain (from 2:1 to 1:2)
- DOR knockout mice show increased anxiety and reduced stress resilience
- Enkephalins modulate gut motility via enteric nervous system DORs
- CSF met-enkephalin <10 pg/mL correlates with treatment-resistant chronic pain
- endogenous opioids — enkephalins are the shortest-acting class of endogenous opioid peptides
- endorphins — enkephalins and beta-endorphin are distinct families; enkephalins act faster but are shorter-lived
- delta opioid receptor — primary target for enkephalins with 100-fold greater affinity than MOR
- mu opioid receptor — enkephalins bind MOR with lower affinity, contributing to analgesia when DOR saturated
- PAG — major site of enkephalin synthesis and origin of descending pain inhibition pathways
- RVM — relay station where PAG enkephalins modulate descending control to dorsal horn
- descending inhibition — enkephalins are the primary neurotransmitter mediating top-down pain suppression
- dorsal horn — enkephalins inhibit substance P and glutamate release from nociceptive terminals in Lamina II
- chronic stress — depletes enkephalin synthesis capacity, creating vulnerability to chronic pain
- opioid tolerance — enkephalin depletion predisposes to rapid tolerance when exogenous opioids introduced
- CRF — enkephalins provide the "STOP" signal balancing CRF "GO" signal in stress response
- HPA axis — enkephalins modulate CRF and ACTH release, preventing runaway stress activation
- substance P — enkephalins directly inhibit substance P release from C-fiber terminals
- chronic pain — enkephalin deficiency from chronic stress is a primary mechanism in centralized pain syndromes
- placebo effect — placebo analgesia operates substantially through enkephalin release in PAG and ACC
- depression — enkephalin deficiency contributes to anhedonia and emotional pain in chronic stress
- neuroinflammation — enkephalins from microglia and astrocytes provide anti-inflammatory signaling in CNS
- nucleus accumbens — DOR-mediated enkephalin signaling contributes to reward processing and social bonding
- locus coeruleus — receives enkephalinergic inhibition, modulating noradrenergic arousal output
- vagus nerve — enkephalinergic neurons in NTS modulate vagal afferent processing
- exercise — acute exercise dramatically increases enkephalin mRNA and protein, contributing to "runner's high"
- BDNF — exercise-induced enkephalin and BDNF release are synergistic for neuroprotection
- IL-6 — enkephalins from immune cells inhibit IL-6 production at inflammation sites
- macrophage polarization — enkephalins promote M2 (resolution) macrophage phenotype
- resilience — enkephalin reserve capacity is a biomarker of stress resilience and pain threshold
- allostatic load — enkephalin depletion is a measurable component of cumulative stress burden
- Module 3 — pain modulation, descending inhibition, endogenous opioid systems
- Module 5 — organs I, HPA axis, stress response balancing
- Module 6 — diagnosis, chronic stress patterns, pain syndromes
- Module 8 — advanced integration, neuroimmune interfaces, placebo mechanisms